SCHEMBL17786117

SCHEMBL17786117

Nc1ccccc1C(=O)N(c1ccccc1)C1CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 12/20 0.58
SLC6A2 P23975 11/20 0.58
SLC6A3 Q01959 5/20 0.58
KCNH2 Q12809 4/20 0.57
CYP2D6 P10635 2/20 0.56
KDM4E B2RXH2 2/20 0.42
CHRM2 P08172 1/20 0.40
CHRM3 P20309 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
MITF O75030 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
PAX8 Q06710 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
OPRM1 P35372 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9785692 0.80 SLC6A4 (0.63) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL6160138 0.79 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL6621005 0.79 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL8553350 0.79 SLC6A4 (0.51) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
Hydrochloric Acid SCHEMBL22797859 0.78 SLC6A2 (0.53) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL4560310 0.75 SLC6A4 (0.62) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL19064185 0.74 IKBKB (0.43) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
Hydrochloric Acid SCHEMBL9785681 0.74 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL4634790 0.74 SLC6A2 (0.69) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6
SCHEMBL4634803 0.73 SLC6A4 (1.00) SLC6A4SLC6A2SLC6A3KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016086153-A2 USE OF TETRAHYDRO!NDAZOLYLBEIMZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) ESANEX, INC. (US) 2016-06-02 WO disclosed